Remus Pharmaceuticals Ltd

The transcript provided does not mention any current or future plans for fundraising through debt or equity. Key points: - No direct discussion or indication of debt or equity fundraising activities during the Q2 and H1 FY2026 earnings call. - Management focused mainly on organic growth, operational performance, expansion of B2C and B2B segments, geographic expansion, and margin improvement. - Comments relate to acquisitions already completed (e.g., US subsidiary acquired in 2024), but no new fundraising mentioned. - There is no guidance or statement about raising capital via debt or equity in the near future. Therefore, based on the information in the transcript, there are no announced or planned fundraisings through debt or equity at this time.

- Remus Pharmaceuticals is actively expanding its international footprint, including recent entry into Algeria and plans for subsidiary establishments in new countries such as Kenya, Chile, and Dominican Republic. - The company is focusing on building its B2C segment, including launching new products like Rivastigmine patches and other dermal patches, indicating investment in product development. - They are setting up a new subsidiary for clinical trials and research services, which will contribute to future operational growth. - Investments in technology transfer and licensing deals with local manufacturers (e.g., Algeria) are part of strategic efforts to enhance manufacturing collaborations and royalties. - The approach includes strong due diligence and market visits before entering new countries, signaling strategic capital allocation for market expansion. - While exact capex figures or timelines are not disclosed, they aim to grow B2C contributions from 13% to around 20-25% of revenues, implying ongoing investment in building brand presence and infrastructure.

- US business currently contributes ~80% of consolidated revenues; H1 FY25 to H1 FY26 saw ~40% growth in US standalone revenues due to new market entries and customer acquisitions. - Both US subsidiary and standalone/emerging market businesses expected to grow proportionately, maintaining or slightly adjusting revenue shares. - Emerging market revenues currently ~20%; management anticipates this to increase to 25-30% over time as B2C segment grows rapidly. - B2C business increased from 4% to 13% of revenues in H1 FY26; targeted to reach 18-20% by end-FY26 and 20-25% within next 1.5 years. - Overall revenue growth supported by expansion into new geographies including Algeria, Kenya, Chile, Dominican Republic, and African markets. - High-margin emerging markets and B2C growth expected to improve blended PAT margins from current ~5% towards 8-10% in near future. - Management focused on expanding niche, high-value products, and building direct brand presence for sustained volume and value growth.

- Remus Pharmaceuticals expects growth in both B2B and B2C segments, with a strong focus on expanding the higher-margin B2C business. - B2C revenue contribution grew from 4% to 13% in H1 FY26, with a target to reach around 18-20% by the end of the financial year and 20-25% within the next 1.5 years. - EBITDA margins for B2C are around 35%, significantly higher than the current overall EBITDA margin of about 7%. - Consolidated PAT margin currently at ~5%, with management aiming to improve it to 8-10% over the next 1-2 years. - US subsidiary, which contributes ~80% of revenue, is stable with gradual growth expected; emerging markets to gain higher revenue share over time. - Positive outlook on PAT growth driven by increasing B2C share, new subsidiaries, and operational efficiencies. - Management indicates a steady growth trajectory without specific numeric guidance but expects continued strong earnings momentum.

The transcript provided for Remus Pharmaceuticals Limited's H1 FY2026 Earnings Call does not mention any specific details on current or expected order book or pending orders. Key points related to business operations and growth include: - Focus on expanding US and emerging markets with increase in US subsidiary revenues. - Growth in B2C segment from 4% to 13% of total revenues, with targets of 18-20% by year-end. - Expansion into several new geographies like Algeria, Chile, Dominican Republic, Kenya, and Africa. - US subsidiary (Espee) entering new markets and growing distribution. - No explicit reference to order backlog or pending orders during the call. Hence, no direct information on order book or pending orders is available in the transcript.